RYTM Rhythm Pharmaceuticals, Inc.
Healthcare$89.83+0.00%OpenMarket Cap: $6.16B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
48.58
P/S
27.72
EV/EBITDA
-33.82
DCF Value
$-377.48
FCF Yield
-2.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.4%
Operating Margin
-90.9%
Net Margin
-93.3%
ROE
-203.2%
ROA
-45.8%
ROIC
-56.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $60.1M | 88.1% | $-52.4M | $-55.6M | $— | — |
| Q4 null | $57.3M | 91.6% | $-47.1M | $-47.5M | $— | — |
| FY null | $189.8M | 89.7% | $-192.0M | $-196.5M | $— | — |
| Q3 null | $51.3M | 89.3% | $-52.7M | $-52.9M | $— | — |
| Q2 null | $48.5M | 88.6% | $-45.3M | $-46.6M | $— | — |
| Q1 null | $32.7M | 88.8% | $-47.0M | $-49.5M | $— | — |
| Q4 null | $41.8M | 90.9% | $-41.3M | $-43.3M | $— | — |
| FY null | $130.1M | 89.7% | $-265.5M | $-260.6M | $— | — |
| Q3 null | $33.3M | 88.5% | $-43.9M | $-43.6M | $— | — |
| Q2 null | $29.1M | 89.9% | $-40.5M | $-32.3M | $— | — |
| Q1 null | $26.0M | 89.2% | $-139.9M | $-141.4M | $— | — |
| Q4 2023 | $24.2M | 86.7% | $-41.3M | $-41.6M | $-0.70 | — |